These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 21744090)

  • 1. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.
    Braunlin EA; Harmatz PR; Scarpa M; Furlanetto B; Kampmann C; Loehr JP; Ponder KP; Roberts WC; Rosenfeld HM; Giugliani R
    J Inherit Metab Dis; 2011 Dec; 34(6):1183-97. PubMed ID: 21744090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Abnormalities in Egyptian Children with Mucopolysaccharidoses.
    Selim L; Abdelhamid N; Salama E; Elbadawy A; Gamaleldin I; Abdelmoneim M; Selim A
    J Clin Diagn Res; 2016 Nov; 10(11):SC05-SC08. PubMed ID: 28050459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study.
    Sestito S; Rinninella G; Rampazzo A; D'Avanzo F; Zampini L; Santoro L; Gabrielli O; Fiumara A; Barone R; Volpi N; Scarpa M; Tomanin R; Concolino D
    Orphanet J Rare Dis; 2022 Jun; 17(1):251. PubMed ID: 35768874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac manifestations of the mucopolysaccharidoses.
    Schieken RM; Kerber RE; Ionasescu VV; Zellweger H
    Circulation; 1975 Oct; 52(4):700-5. PubMed ID: 808361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
    Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
    Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists.
    Boffi L; Russo P; Limongelli G
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):122. PubMed ID: 30442163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular changes in children with mucopolysaccharide disorders.
    Mohan UR; Hay AA; Cleary MA; Wraith JE; Patel RG
    Acta Paediatr; 2002; 91(7):799-804. PubMed ID: 12200906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac structural involvement in mucopolysaccharidoses.
    Rigante D; Segni G
    Cardiology; 2002; 98(1-2):18-20. PubMed ID: 12373042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III.
    Lin HY; Chen MR; Lin SM; Hung CL; Niu DM; Chang TM; Chuang CK; Lin SP
    Orphanet J Rare Dis; 2019 Jun; 14(1):140. PubMed ID: 31196149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI].
    Azak E; Gündüz M
    Turk Kardiyol Dern Ars; 2019 Oct; 47(7):587-593. PubMed ID: 31582674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy.
    Kampmann C; Lampe C; Whybra-Trümpler C; Wiethoff CM; Mengel E; Arash L; Beck M; Miebach E
    J Inherit Metab Dis; 2014 Mar; 37(2):269-76. PubMed ID: 24062198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of echocardiographic abnormalities in mucopolysaccharidosis III.
    Wilhelm CM; Truxal KV; McBride KL; Kovalchin JP; Flanigan KM
    Mol Genet Metab; 2018 Jun; 124(2):131-134. PubMed ID: 29735373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.
    Brands MM; Frohn-Mulder IM; Hagemans ML; Hop WC; Oussoren E; Helbing WA; van der Ploeg AT
    J Inherit Metab Dis; 2013 Mar; 36(2):227-34. PubMed ID: 22278137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA.
    Lin HY; Chen MR; Lin SM; Hung CL; Niu DM; Chuang CK; Lin SP
    Orphanet J Rare Dis; 2018 Aug; 13(1):148. PubMed ID: 30157891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.
    Sato Y; Fujiwara M; Kobayashi H; Yoshitake M; Hashimoto K; Oto Y; Ida H
    Mol Genet Metab Rep; 2015 Dec; 5():94-97. PubMed ID: 28649551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [When is surgery needed for minimally symptomatic or asymptomatic acquired valvulopathy?].
    Acar J; Michel PL; de Gevigney G
    Presse Med; 2000 Nov; 29(34):1867-75. PubMed ID: 11709821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II.
    Lin HY; Chen MR; Lee CL; Lin SM; Hung CL; Niu DM; Chang TM; Chuang CK; Lin SP
    Orphanet J Rare Dis; 2021 Feb; 16(1):99. PubMed ID: 33622387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echocardiographic abnormalities in type IV mucopolysaccharidosis.
    John RM; Hunter D; Swanton RH
    Arch Dis Child; 1990 Jul; 65(7):746-9. PubMed ID: 2117422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular manifestations of Alkaptonuria.
    Pettit SJ; Fisher M; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2011 Dec; 34(6):1177-81. PubMed ID: 21506017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.